HC Wainwright Has Bullish Forecast for PLX Q1 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for Protalix BioTherapeutics in a research note issued to investors on Monday, April 28th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.08 per share for the quarter, up from their prior forecast of $0.03. HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q2 2025 earnings at $0.11 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.13 EPS and FY2025 earnings at $0.45 EPS.

Separately, StockNews.com lowered Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 20th.

Protalix BioTherapeutics Stock Down 2.3 %

NYSE:PLX opened at $3.00 on Thursday. The business’s 50-day moving average price is $2.50 and its 200 day moving average price is $2.08. The firm has a market cap of $234.10 million, a P/E ratio of -23.08 and a beta of 0.46. Protalix BioTherapeutics has a 52-week low of $0.82 and a 52-week high of $3.10.

Hedge Funds Weigh In On Protalix BioTherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Y Intercept Hong Kong Ltd acquired a new position in shares of Protalix BioTherapeutics in the 4th quarter valued at $35,000. Sanctuary Advisors LLC acquired a new position in shares of Protalix BioTherapeutics in the 3rd quarter valued at $38,000. PFG Investments LLC acquired a new position in shares of Protalix BioTherapeutics in the 4th quarter valued at $39,000. Virtu Financial LLC acquired a new position in shares of Protalix BioTherapeutics in the 3rd quarter valued at $44,000. Finally, Cubist Systematic Strategies LLC boosted its position in shares of Protalix BioTherapeutics by 24.1% in the 4th quarter. Cubist Systematic Strategies LLC now owns 29,307 shares of the company’s stock valued at $55,000 after purchasing an additional 5,686 shares during the period. Institutional investors and hedge funds own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.